搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
FierceBiotech
2 小时
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule
Athira Pharma has been on a bumpy road in recent years, and now the company is restructuring and shedding weight to try to ...
FierceBiotech
3 小时
Stryker strikes again, acquiring brain surgery devicemaker Nico
After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh ...
FierceBiotech
5 小时
Protein found in hibernating squirrels could become first cataract drug treatment: study
A surgeon makes small incisions in the eye, sucks out the cloudy lens and replaces it with an artificial lens implant.
FierceBiotech
6 小时
Politan prevails in Masimo proxy fight, gaining 2 board seats and ousting CEO Joe Kiani
Masimo’s long-running proxy fight has come to a close, at least for now. | Masimo’s long-running proxy fight has come to a ...
FierceBiotech
7 小时
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
FierceBiotech
7 小时
Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial
Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...
FierceBiotech
8 小时
Chutes & Ladders—2 Kite vets fly over to Kyverna Therapeutics
Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...
FierceBiotech
10 小时
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
FierceBiotech
13 小时
Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈